Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

70.39 -0.66 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corp

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Where Incyte Stands With Analysts
Within the last quarter, Incyte (NASDAQ:INCY) has observed the following an... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: 
Via Benzinga
Expert Ratings For Incyte
Over the past 3 months, 6 analysts have published their opinion on Incyte (NASDAQ: 
Via Benzinga
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
From Incyte
Via Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer... 
Via FinancialNewsMedia
Topics Death
Exposures Death
This Biotech Is Working With Pfizer, Merck KGaA, Roche, and Other Leaders To Develop a Better Standard of Care for Breast Cancer
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the... 
Via Benzinga
Cramer Shares His Thoughts On Incyte, Corning And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Incyte Corporation (NASDAQ: 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) supplemental marketing application seeking approval for ruxolitinib cream 1.5% (Opzelura), a... 
Via Benzinga
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket?
Airbnb, Inc (NASDAQ: ABNB), Fortinet, Inc (NASDAQ: FTNT), Palo Alto Networks, Inc (NASDAQ: PANW), Lucid Group, Inc (NASDAQ: LCID), Zscaler, Inc (NASDAQ: ZS), and Datadog, Inc (... 
Via Benzinga
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
Annual Changes To The Nasdaq-100 Index
The reconstituted Nasdaq index for 2022 (effective Dec. 20, 2021) has six new members; they replace FOX, TCOM, INCY, CDW, CERN, and CHKP. 
Via Talk Markets
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
From Incyte
Via Business Wire
7 CEOs That Ought to Follow Jack Dorsey Out the Door
Jack Dorsey stepped down as Twitter CEO despite stock gains, but not every CEO can say the same. Here are seven CEOs who need to go. 
Via InvestorPlace
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit... 
Via FinancialNewsMedia
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
7 Stocks 'On Sale' This Holiday Season
This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have... 
Via Talk Markets
7 Stocks 'On Sale' This Holiday Season
The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In... 
Via Benzinga
Topics Stocks
Exposures US Equities
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
Stocks Most Impacted by 7-10 Year Treasuries
A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
From Incyte
Via Business Wire
Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript
INCY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.